Health Trials

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.

Participants needed: 120
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: Jun 25, 2026Locations: 18
Eligibility criteria

Signed the informed consent [+8]

Subjects with acute promyelocytic leukemia (APL) or chronic myelogenous leukemia... [+27]

Read more
Status: Not yet recruiting

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).

Participants needed: 550
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: Jun 4, 2026
Eligibility criteria

Histologically or cytologically confirmed first-line (1L), extensive-stage (ES)... [+4]

Received any kind of platinum or etoposide treatment for limited stage (LS) SCLC... [+5]

Read more
Status: Recruiting

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms

Participants needed: 120
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: May 22, 2026Locations: 20
Eligibility criteria

Documented locally advanced or metastatic SCLC, large cell neuroendocrine cancer... [+8]

Chemotherapy, biological therapy, immunotherapy, , targeted therapy (including s... [+7]

Read more
Status: Recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.

Participants needed: 160
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: Apr 30, 2026Locations: 17
Eligibility criteria

Signed the informed consent form voluntarily and agreed to follow the program re... [+19]

Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, targeted... [+25]

Read more
Status: Recruiting

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

Participants needed: 280
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: Mar 23, 2026Locations: 17
Eligibility criteria

Age: ≥18 years [+19]

Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, targeted... [+13]

Read more
Status: Recruiting

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

Participants needed: 470
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: Jan 29, 2026Locations: 39
Eligibility criteria

Signed the informed consent voluntarily and agreed to follow the program require... [+26]

Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, targeted... [+25]

Read more